Stock Market Review #shorts 30AUG23

Risk adjusted net present value: What is the current valuation of CRISPR Therapeutics’s CTX-131?

CTX-131 is a gene-modified cell therapy commercialized by CRISPR Therapeutics, with a leading Phase II program in Cervical Cancer;Endometrial Cancer.

December 14, 2024

D.C. Hospital Gets a Wake-Up Call to Chagas Disease

Researchers from one Washington, D.C., center confirmed that there was a high prevalence of Chagas disease in a sample of Latin American immigrants hospitalized with

July 18, 2024

Unexciting Earnings Season

The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. This update is our first since

May 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.